Treatment with Next-Generation ALK Inhibitors Fuels Plasma ALK Mutation Diversity

BACKGROUND: Acquired resistance to next-generation ALK tyrosine kinase inhibitors (TKIs) is often driven by secondary ALK mutations. Here we investigated utility of plasma genotyping for identifying ALK resistance mutations at relapse on next-generation ALK TKIs. METHODS: We analyzed 106 plasma spec...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Clin Cancer Res
Main Authors: Dagogo-Jack, Ibiayi, Rooney, Marguerite, Lin, Jessica J., Nagy, Rebecca J., Yeap, Beow Y., Hubbeling, Harper, Chin, Emily, Ackil, Jennifer, Farago, Anna F., Hata, Aaron N., Lennerz, Jochen K., Gainor, Justin F., Lanman, Richard B., Shaw, Alice T.
Format: Artigo
Jezik:Inglês
Izdano: 2019
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6858956/
https://ncbi.nlm.nih.gov/pubmed/31358542
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-19-1436
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki